查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球雙相情感障礙市場（2022-2028）：按藥物類別（情緒穩定劑、抗驚厥藥）和類型（雙相 I 型障礙、雙相 II 型障礙）分列的規模、份額、增長分析和預測
市場調查報告書
商品編碼
1244243

全球雙相情感障礙市場（2022-2028）：按藥物類別（情緒穩定劑、抗驚厥藥）和類型（雙相 I 型障礙、雙相 II 型障礙）分列的規模、份額、增長分析和預測

Global Bipolar Disorder Market Size, Share, Growth Analysis, By Drug Class(Mood Stabilizers, Anticonvulsants), By Type(Bipolar I Disorder, Bipolar II Disorder) - Industry Forecast 2022-2028
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球躁鬱症市場規模預計將從 2021 年的 53 億美元增長到 2028 年的 61 億美元，預測期內的複合年增長率超過 2.12%。.

近年來雙相情感障礙的全球患病率一直在上升，推動了市場的增長。 據世界衛生組織稱，雙相情感障礙是全球第六大殘疾原因，全世界估計有 6000 萬人受到影響。 雙相情感障礙患病率的增加歸因於生活方式改變、壓力水平增加和遺傳等因素。

在本報告中，我們研究了全球雙相情感障礙市場，提供了市場概況、對市場的各種影響因素的分析、技術和創新趨勢、市場規模的趨勢和預測，以及各個細分市場和細分市場的細分地區、競爭格局、主要公司概況等。

內容

執行摘要

市場概覽

母市場分析

市場概覽

市場規模

  • 市場動態
  • 司機
  • 機會
  • 約束因素
  • 任務
  • SWOT 分析

主要市場洞察

  • 技術分析
  • 價格分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 知識產權分析
  • 貿易分析
  • 啟動分析
  • 原材料分析
  • 創新矩陣
  • 管道產品分析
  • 宏觀經濟指標

COVID-19 的影響

市場動態和前景

  • 市場動態
  • 司機
  • 機會
  • 約束因素
  • 任務
  • 監管狀況
  • SWOT 分析
  • 波特的分析
  • Skyquest 對未來顛覆的特別洞察
  • 全球雙相情感障礙市場：按藥物分類
  • 情緒穩定劑
  • 抗驚厥藥
  • 抗精神病藥
  • 抗抑鬱藥
  • 抗焦慮藥
  • 其他

全球雙相情感障礙市場：按類型分類

  • I型雙相情感障礙
  • 雙相 II 型障礙
  • 循環障礙
  • 其他

按地區劃分的市場規模

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

主要公司簡介

  • 競爭格局
  • Allergan
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Abbott
  • Bristol-Myers Squibb
  • Johnson &Johnson
  • Pfizer Inc.
  • Cephalon Inc.
  • Otsuka America Pharmaceutical Inc.
  • Gedeon Richter plc
簡介目錄
Product Code: SQSG45I2027

Global Bipolar Disorder Market was valued at USD 5.3 Billion in 2021, and it is expected to reach a value of USD 6.1 Billion by 2028, at a CAGR of more than 2.12% over the forecast period (2022-2028).

The global bipolar disorder market refers to the market for pharmaceuticals and treatment options used to manage bipolar disorder, which is a mental health condition characterized by episodes of depression and mania. The market for bipolar disorder treatment is driven by several factors, including the increasing prevalence of the disorder, growing awareness and diagnosis of the condition, and the introduction of new and innovative treatment options. The market includes a wide range of products such as mood stabilizers, antipsychotics, antidepressants, and psychotherapy.

Top-down and bottom-up approaches were used to estimate and validate the size of Global Bipolar Disorder Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

Global bipolar disorder market is segmented based on the drug class, type, and region. Based on the drug class, the global bipolar disorder market is segmented as mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressant drugs, antianxiety drugs and others. Based on type, the global bipolar disorder market is segmented as, bipolar I disorder, bipolar II disorder, cyclothymic disorder, and others. Based on region, it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Driver

The global prevalence of bipolar disorder has been increasing in recent years, which is driving the growth of the bipolar disorder market. According to the World Health Organization, bipolar disorder is the sixth leading cause of disability worldwide, affecting an estimated 60 million people globally. The increasing prevalence of bipolar disorder is attributed to factors such as changing lifestyles, increasing stress levels, and genetic factors.

Restraint

Despite significant advances in the diagnosis and treatment of the bipolar disorder, the underlying causes of the condition are not yet fully understood. This can limit the development of effective treatments and make it more challenging to identify patients who are at risk of developing bipolar disorder.

Market Trends

Personalized medicine is an emerging trend in the bipolar disorder market, with a growing focus on developing targeted therapies that address the specific needs of individual patients. Advances in genetics and biomarker research are helping to identify subtypes of bipolar disorder, which could lead to more effective and personalized treatments. Additionally, the development of digital health tools, such as mobile apps and wearables, is enabling the collection of real-time patient data that can be used to inform personalized treatment plans. As the demand for personalized medicine continues to grow, we can expect to see more investment in research and development of targeted therapies for bipolar disorder.

Table of Contents

Executive Summary

Market overview

  • Exhibit: Executive Summary - Chart on Market Overview
  • Exhibit: Executive Summary - Data Table on Market Overview
  • Exhibit: Executive Summary - Chart on Global Global Bipolar Disorder Market Characteristics
  • Exhibit: Executive Summary - Chart on Market by Geography
  • Exhibit: Executive Summary - Chart on Market Segmentation
  • Exhibit: Executive Summary - Chart on Incremental Growth
  • Exhibit: Executive Summary - Data Table on Incremental Growth
  • Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy-scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Global Bipolar Disorder Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
  • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
  • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
  • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
  • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
  • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact
  • Global Global Bipolar Disorder Market by Drug Class
  • Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
  • Mood Stabilizers
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Anticonvulsants
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Antipsychotic Drugs
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Antidepressant Drugs
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Antianxiety Drugs
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Other
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)

Global Global Bipolar Disorder Market by Type

  • Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
  • Bipolar I Disorder
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Bipolar II Disorder
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Cyclothymic Disorder
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Others
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
  • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
  • Exhibit: company positioning matrix, 2021
    • Top companies market Share
  • Exhibit: Pie chart analysis on company market share, 2021(%)
  • Allergan (Ireland)AstraZeneca (UK)Eli Lilly and Company (US)GlaxoSmithKline (UK)Abbott (US)Bristol-Myers Squibb (US)Johnson & Johnson (US)Pfizer Inc. (US)Cephalon Inc. (US)Otsuka America Pharmaceutical Inc. (US)Gedeon Richter plc (Hungary)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Allergan (Ireland)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • AstraZeneca (UK)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Eli Lilly and Company (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • GlaxoSmithKline (UK)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Abbott (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Bristol-Myers Squibb (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Johnson & Johnson (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Pfizer Inc. (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cephalon Inc. (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Otsuka America Pharmaceutical Inc. (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Gedeon Richter plc (Hungary)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments